Touchstone
Last syncOct 31, 2026, 6:54 PM ET

ALMS

Alumis Inc. Health Care Pharmaceutical Preparations Russell 3000
$6.73Close $4.55 – $30.3052-week range Nov 12, 2026Next report

Highlights

Cautions

  • Not in an uptrend 1 of 8 trend conditions
  • Lagging the market RS 2 · weaker than 98% of stocks over 12 months
  • Far from its high 78% below its 52-week high
  • Distribution down-day volume 1.7× up-day volume over 50 sessions
  • Earnings shrinking EPS −244% year on year
  • Results soon Nov 12, 2026, in 11 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 13, 2026
Off 12-month high 78%
1wk down 0.7% price change
1mo down 8.9% price change
12-month return up 44% market up 11% · its own up 32%
F-score — — Not assessed
Altman Z — Unknown
P/E — price / earnings
PEG — P/E / EPS growth
P/B — price / book
Earnings yield — EBIT / enterprise value
Cheaper than — of the market · not assessed
Revenue growth — year on year
EPS growth down 244% latest quarter
Sales growth down 38% latest quarter · +52 pts
ROE down 87% return on equity
Free cash margin down 1539% -$370.2M FCF
D/E — long-term debt / equity
Net debt / EBITDA —
Interest cover —EBIT / interest

Trade setup

ATR% 7.9% $0.53 a day · 2×ATR $5.67
RS 2 / 99 vs the universe
Trend 1 / 8 trend template
Relative volume 0.7× vs 50-day average
Up/down volume 0.59 50 sessions
Implied move — no option chain · report Nov 12, 2026
Trend template · 1 of 8
  • At least 30% above the 52-week low: passes

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged
  • No restatement or impairment
  • Equity positive
  • Interest covered
  • No material dilution
  • Profits tracking cash
  • Margins and revenue not shrinking
Last reported Aug 13, 2026
Last shock Sep 1, 2026-57% in one session15.9× volumeon an SEC filing-29% since

Financials

3 fiscal years · from filings
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$243.3M
-$500M $0 FY23 FY24 FY25 FY2023 · -$155.0M FY2024 · -$294.2M FY2025 · -$243.3M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$370.2M
-$500M $0 FY23 FY24 FY25 FY2023 · -$134.5M FY2024 · -$256.8M FY2025 · -$370.2M
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology
  • Cash
  • Long-term debt
$0 $200M FY23 FY24 FY25 FY2023 · Cash $46.0M FY2024 · Cash $169.5M FY2025 · Cash $89.7M
  FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue — — $24.1M
Operating income -$158.2M -$300.8M -$453.8M
Net income -$155.0M -$294.2M -$243.3M
Net margin — — -1012%
Earnings per share -$72.08 -$10.38 -$2.86
Free cash flow -$134.5M -$256.8M -$370.2M
Free cash margin — — -1539%
Cash $46.0M $169.5M $89.7M
Shareholders' equity -$339.3M $260.1M $301.3M

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 13, 2026 Quarterly ↗ Jun 30, 2026 44d
May 14, 2026 Quarterly ↗ Mar 31, 2026 44d
Mar 19, 2026 Annual ↗ Dec 31, 2025 78d
Nov 13, 2025 Quarterly ↗ Sep 30, 2025 44d
Aug 13, 2025 Quarterly ↗ Jun 30, 2025 44d
May 14, 2025 Quarterly ↗ Mar 31, 2025 44d
Mar 19, 2025 Annual ↗ Dec 31, 2024 78d
Nov 13, 2024 Quarterly ↗ Sep 30, 2024 44d
Aug 13, 2024 Quarterly ↗ Jun 30, 2024 44d

Current reports

FiledDisclosed
Sep 1, 2026 Other events ↗
Aug 13, 2026 Results ↗
Aug 10, 2026 Other events ↗
Jul 2, 2026 Shareholder vote ↗
Jun 29, 2026 Other events ↗
May 14, 2026 Results ↗
Mar 30, 2026 Other events ↗
Mar 19, 2026 Results ↗
Jan 9, 2026 Results · Other events ↗
Jan 6, 2026 Other events ↗
Jan 2, 2026 Other events ↗
Nov 13, 2025 Results ↗